Literature DB >> 12704576

Animal models of FSGS: lessons for pathogenesis and treatment.

Agnes B Fogo1.   

Abstract

Glomerulosclerosis in a heterogeneous pattern, ie, focal and segmental glomerulosclerosis (FSGS), is a common endpoint in a variety of settings, including idiopathic FSGS, and scarring secondary to other renal or systemic diseases. These different causes contribute to the diverse clinical outcomes of histological focal sclerosis, and the varying histologic manifestations of sclerosis. Numerous models have been established in the rat that aim to mirror the various elements of human glomerulosclerosis. With the availability of knockout gene technology, many, but not all of these models have been translated to mouse species. This review will focus on the remnant kidney model, the podocyte injury models of puromycin aminonucleoside or adriamycin injection, and examples of newly developed genetic models, such as knockout of CD2 associated protein (CD2AP). Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704576     DOI: 10.1053/snep.2003.50015

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  40 in total

1.  Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin.

Authors:  Tobias B Huber; Christopher Kwoh; Hui Wu; Katsuhiko Asanuma; Markus Gödel; Björn Hartleben; Ken J Blumer; Jeffrey H Miner; Peter Mundel; Andrey S Shaw
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

2.  Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Cheryl Smith; Kevin Engels; Jean L Olson; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-23

3.  Protein synthesis inhibition as a potential strategy for metabolic down-regulation.

Authors:  Melissa C Evans; Robert F Diegelmann; R Wayne Barbee; M Hakam Tiba; Eric Edwards; Sue Sreedhar; Kevin R Ward
Journal:  Resuscitation       Date:  2007-01-23       Impact factor: 5.262

4.  Adriamycin-Induced Models of VACTERL Association.

Authors:  D Mc Laughlin; P Hajduk; P Murphy; P Puri
Journal:  Mol Syndromol       Date:  2013-02

5.  Gq signaling causes glomerular injury by activating TRPC6.

Authors:  Liming Wang; Grant Jirka; Paul B Rosenberg; Anne F Buckley; Jose A Gomez; Timothy A Fields; Michelle P Winn; Robert F Spurney
Journal:  J Clin Invest       Date:  2015-04-06       Impact factor: 14.808

6.  5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy.

Authors:  A Ozcan; K Ware; E Calomeni; T Nadasdy; R Forbes; A A Satoskar; G Nadasdy; B H Rovin; L A Hebert; S V Brodsky
Journal:  Am J Nephrol       Date:  2012-04-02       Impact factor: 3.754

7.  Ret is critical for podocyte survival following glomerular injury in vivo.

Authors:  Guoqing Hou; Victoria Wu; Gulmohar Singh; Lawrence B Holzman; Cynthia C Tsui
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-13

8.  Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.

Authors:  Harindra Rajasekeran; Heather N Reich; Michelle A Hladunewich; Daniel Cattran; Julie A Lovshin; Yuliya Lytvyn; Petter Bjornstad; Vesta Lai; Josephine Tse; Leslie Cham; Syamantak Majumder; Bridgit B Bowskill; M Golam Kabir; Suzanne L Advani; Ian W Gibson; Manish M Sood; Andrew Advani; David Z I Cherney
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-15

9.  Nitro-oleic acid protects against adriamycin-induced nephropathy in mice.

Authors:  Shanshan Liu; Zhanjun Jia; Li Zhou; Ying Liu; Hong Ling; Shu-Feng Zhou; Aihua Zhang; Yaomin Du; Guangju Guan; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2013-03-13

10.  Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria.

Authors:  Chunsun Dai; Donna B Stolz; Lawrence P Kiss; Satdarshan P Monga; Lawrence B Holzman; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.